Literature DB >> 23946031

Warfarin: its highs and lows.

Zack Dumont1, Merunka Mordasiewicz, Lynette Kosar, Brenda Schuster.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23946031      PMCID： PMC3743701     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  10 in total

Review 1.  Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Anne Holbrook; Sam Schulman; Daniel M Witt; Per Olav Vandvik; Jason Fish; Michael J Kovacs; Peter J Svensson; David L Veenstra; Mark Crowther; Gordon H Guyatt
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed.

Authors:  Lynette Kosar; Margaret Jin; Rejina Kamrul; Brenda Schuster
Journal:  Can Fam Physician       Date:  2012-08       Impact factor: 3.275

4.  Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study.

Authors:  Y-K Kim; R Nieuwlaat; S J Connolly; S Schulman; K Meijer; N Raju; S Kaatz; J W Eikelboom
Journal:  J Thromb Haemost       Date:  2009-10-14       Impact factor: 5.824

5.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

Authors:  Ron Pisters; Deirdre A Lane; Robby Nieuwlaat; Cees B de Vos; Harry J G M Crijns; Gregory Y H Lip
Journal:  Chest       Date:  2010-03-18       Impact factor: 9.410

6.  Rate versus rhythm control in atrial fibrillation.

Authors:  Grace Frankel; Rejina Kamrul; Lynette Kosar; Brent Jensen
Journal:  Can Fam Physician       Date:  2013-02       Impact factor: 3.275

7.  Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial.

Authors:  Sam Schulman; Sameer Parpia; Clare Stewart; Lisa Rudd-Scott; Jim A Julian; Mark Levine
Journal:  Ann Intern Med       Date:  2011-11-15       Impact factor: 25.391

8.  Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.

Authors:  John A Cairns; Stuart Connolly; Sean McMurtry; Michael Stephenson; Mario Talajic
Journal:  Can J Cardiol       Date:  2011 Jan-Feb       Impact factor: 5.223

9.  Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial.

Authors:  Michael J Kovacs; Marc Rodger; David R Anderson; Beverly Morrow; Gertrude Kells; Judy Kovacs; Eleanor Boyle; Philip S Wells
Journal:  Ann Intern Med       Date:  2003-05-06       Impact factor: 25.391

10.  Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium.

Authors:  M Anthony; K Romero; D C Malone; L E Hines; L Higgins; R L Woosley
Journal:  Clin Pharmacol Ther       Date:  2009-07-08       Impact factor: 6.875
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.